Image For Activity Cover
8 Hour Online Buprenorphine Training
This is an 8 hour training course for physicians and physician assistants who wish to prescribe buprenorphine to treat opioid use disorder (OUD). This training will satisfy the 8 hour training requirement mandated by the MATE Act.

PLEASE NOTE: This is NOT the Half and Half MAT waiver course.
Target Audience
This activity will assist physicians and physician assistants (PAs) who wish to prescribe buprenorphine for the treatment of opioid use disorders.
Educational Objectives

At the conclusion of this activity, learners should be able to:

  • Review addiction identification and evidence-based treatments.
  • Discuss the pharmacology of opioids as it relates to treatment of opioid use disorder (OUD) patients.
  • Describe the fundamentals of office-based opioid treatment including the treatment of the co-morbid patient.
  • Explain the process of buprenorphine induction as well as stabilization and maintenance.
  • Discuss other approved antagonist and agonist medications to treat OUD.
  • Discuss basic office protocols including medical record documentation and confidentially.
  • Utilize evidence-based resources to ensure providers have the confidence to prescribe buprenorphine for patients with OUD. 

Fee: No cost 

Method of participation in the activity

To be awarded a maximum of 8 AMA PRA Category 1 Credits™ or 8 AAPA Category 1 CME credits you must:

  • Review 8 training modules (8 hours) provided in this activity.
  • Complete a final evaluation and follow instructions at the end of the course regarding how to retrieve your certificate*.

*Credit will not be awarded unless all components of the program are completed. Partial credit will not be awarded.

Availability: On-Demand
Expires on Nov 30, 2024
Cost: FREE
Credit Offered:
8 CME Credits
8 PA-CME Credits
8 Other Professionals Credits
The content on this site is intended solely to inform and educate medical professionals. This site shall not be used for medical advice and is not a substitute for the advice or treatment of a qualified medical professional.

Funding for this initiative was made possible (in part) by grant nos. 6H79TI081968 and 1H79TI083343 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

For Buprenorphine Training Inquiries, email PCSS.


Powered By